Loading
CRG-150 is an experimental autologous gene-edited regulatory T-cell therapy from CoRegen, in phase 1 trials for relapsed or refractory HR-positive HER2-negative breast cancer, triple-negative breast cancer and prostate cancer.
CRG-150 (SRC-3KO Treg) is an autologous gene-edited regulatory T-cell therapy (Treg) from CoRegen, with Baylor College of Medicine as partner. A patient's own regulatory T cells with the SRC-3 gene disrupted, given back as adoptive cell therapy. Its furthest stage is phase 1, for relapsed or refractory HR-positive HER2-negative breast cancer, triple-negative breast cancer and prostate cancer. ClinicalTrials.gov registers it in one study linked below. FDA notified the company in June 2026 that the CRG-150 study may proceed; phase 1/2 NCT07730125 not yet recruiting, start listed as November 2026. Whether it works in people has not been established unless a trial below reports it.
A patient's own regulatory T cells with the SRC-3 gene disrupted, given back as adoptive cell therapy. Connects to NCOA3.
1.CRG-150 slips into a pocket on NCOA3.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CRG-150" OR ABSTRACT:"CRG-150" OR TITLE:"SRC-3KO Treg" OR ABSTRACT:"SRC-3KO Treg") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CRG-150, not a curated reading list.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer, Prostate cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer, Prostate cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/